Showing results (1-10 of 230) with videos related to
Sort By:
Pageof 23
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E KarpNature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E KarpClinical Investigation|March 6, 2013
New considerations in the design of clinical trials for the treatment of acute leukemiaChristopher S Hourigan, Judith E KarpCancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E KarpExpert Review of Hematology|October 31, 2015
Precision medicine for acute myeloid leukemiaCatherine Lai, Judith E Karp, Christopher S HouriganJournal of Clinical Medicine|May 2, 2015
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaNestor R Ramos, Clifton C Mo, Judith E Karp, et al.Hematology. American Society of Hematology. Education Program|December 9, 2022
Achieving MRD negativity in AML: how important is this and how do we get there?Christopher S HouriganSeminars in Hematology|April 16, 2026
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?Christopher S HouriganCancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S HouriganCurrent Drug Targets|February 24, 2015
Novel Antigen Targets for Immunotherapy of Acute Myeloid LeukemiaMeghali Goswami, Christopher S HouriganPageof 23